



ASX ANNOUNCEMENT

25 March 2025

US PATENT ALLOWED FOR CHM CDH17 TECHNOLOGY

Melbourne, Australia, 25 March 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the US Patent and Trademark Office (USPTO) has allowed the issuance of a patent application covering the Company's proprietary CHM CDH17 chimeric antigen receptor (CAR) technology, a third-generation CAR-T therapy targeting gastrointestinal cancers.

The allowed patent application 17/050,299, entitled "Compositions and Methods for Retrieving Tumor-related Antibodies and Antigens," provides robust intellectual property protection for Chimeric's CHM CDH17 CAR-T therapy, which uniquely targets CDH17, a protein highly expressed on gastrointestinal cancer cells associated with poor prognosis and metastasis. This allowed patent is expected to provide patent protection until at least 2039.

Chimeric holds exclusive worldwide rights to develop and commercialize this innovative CAR-T technology, which is currently in a first-in-human Phase 1/2 clinical trial at leading US cancer centers, including the Sarah Cannon Research Institute, the University of Pennsylvania, and UChicago Medicine. Preclinical studies published in the highly regarded Nature Cancer, have shown CHM CDH17 CAR-T's capability to eradicate tumors across multiple cancer models while sparing healthy tissue.

Chimeric's CEO, Dr Rebecca McQualter said: "The allowance of this US patent significantly strengthens our intellectual property portfolio and provides critical commercial protection in the world's largest healthcare market. It highlights our commitment to developing pioneering CAR-T therapies and is a pivotal milestone in advancing CHM CDH17 CAR-T therapy toward commercialisation for gastrointestinal cancer patients."

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.



CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR-T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.

Contact

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: investors@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au